Silexion Therapeutics Corp (NASDAQ: SLXN) reports Q2 2025 results

Rhea-AI Filing Summary

Silexion Therapeutics Corp filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. On August 12, 2025, the company issued a press release with these quarterly results, which is attached as Exhibit 99.1.

The company is furnishing this press release under the rules of the Securities Exchange Act, meaning it is provided for informational purposes and is not treated as formally filed under certain liability provisions. Details of the actual second-quarter performance, including specific revenue or profit figures, are contained in the referenced press release rather than in this report.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162025-08-122025-08-120002022416slxn:OrdinarySharesParValue00135PerShareMember2025-08-122025-08-120002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-08-122025-08-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 12, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Silexion Therapeutics Corp issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.

The information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release, dated August 12, 2025, titled “Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: August 12, 2025	By:	/s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics Corp (SLXN) disclose in this 8-K?

Silexion Therapeutics Corp disclosed that it issued a press release announcing its financial results for the second quarter ended June 30, 2025, furnished as Exhibit 99.1.

Which period do the new Silexion (SLXN) results cover?

The financial results announced by Silexion cover the second quarter ended June 30, 2025.

How did Silexion Therapeutics Corp provide its Q2 2025 financial results?

Silexion Therapeutics Corp provided its Q2 2025 financial results through a press release dated August 12, 2025, which is attached to the report as Exhibit 99.1.

Is the Silexion Q2 2025 press release considered filed with the SEC?

No. The information in Item 2.02 and Exhibit 99.1 is furnished, not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Where can investors find detailed Silexion Q2 2025 financial numbers?

Detailed financial figures for Silexion’s second quarter 2025 results are contained in the press release furnished as Exhibit 99.1 to the report.

Who signed the Silexion Therapeutics Corp 8-K for the Q2 2025 results?

The report was signed on behalf of Silexion Therapeutics Corp by Ilan Hadar, the company’s Chief Executive Officer.